Patent Overview
A formulation dossier derived from published materials around Pei Zhengxue's integrated clinical discussions.
Indication: Research on Hematological Diseases, Research on Tumor Supportive Treatment, Discussion on Integrated Traditional Chinese and Western Medicine Protocols
Principle and Advantage
The Lanzhou Formula is most suitable to be packaged as a 'supportive asset package for the window of hematologic tumors and bone marrow failure,' with the selling point not being to replace existing targeted drugs, but rather to build a differentiated position around treatment continuity, tolerability, and comprehensive management.
Scientific Basis: Sixteen-Character Guiding Principle, Integration of Disease and Syndrome, Approach of Supporting and Consolidating the Root
- Suitable as a 'Hematologic Oncology Supportive Care Information Package' rather than a single-point efficacy promotional page.
- More suitable for entering into joint research, data standardization, and investor education, rather than directly engaging in consumer-facing narratives.
- Can be combined with chapters and theoretical pages to form a complete clinical model explanation.
Market Context
Market reference：US AML new cases (2026): 22,720; US leukemia prevalence proxy: 456,481
- AML drug innovation is accelerating, but hematologic recovery, blood transfusion independence, and regimen tolerability remain core endpoints.
- Compared with directly competing head-to-head with targeted drugs, supportive assets are easier to enter into joint research, literature compilation, and clinical collaboration.
- Regulators and capital are both paying attention to acute leukemia, making it easier for partners to understand this market window.
Revuforj (revumenib)
Menin inhibitor · Treatment drugs for relapsed/refractory AML (with susceptible NPM1 mutation).
This represents that AML targeted therapy is still continuously evolving, but also emphasizes the importance of managing treatment continuity and tolerability.
Komzifti (ziftomenib)
Menin inhibitor · Therapeutic agent for relapsed/refractory AML (with susceptible NPM1 mutation).
The consecutive approval of two menin inhibitors indicates that AML remains a high-priority focus for capital and BD.
Rydapt (midostaurin)
FLT3 inhibitor · Newly diagnosed FLT3-mutated positive AML, used in combination with standard chemotherapy.
This demonstrates that the commercial market for AML already has a mature standard drug ecosystem.
Related Books
Research on Pei Zhengxue's Formulation Series
Research on Pei Zhengxue's Series of Formulas and Medicines / Compiled by Zhang Chouchou — Lanzhou: Gansu Science and Te.
Collected Medical Experience of Pei Zhengxue
Collected Medical Experiences of Professor Pei Zhengxue / Compiled and authored by Pei Zhengxue Lanzhou: Gansu Science a.
Cooperation
Suitable for historical data compilation, reorganization of public literature, discussion on potential formulation research, and early-stage collaboration assessment; it is not appropriate to disseminate independently without a theoretical background.
This page is for academic exchange and collaboration reference and does not constitute medical advice, product marketing, or efficacy claims.